The company made this announcement during trading hours today, 22 March 2010.
Meanwhile, the BSE Sensex was down 133.97 points, or 0.76% to 17,444.26.
On BSE, 1.96 lakh shares were traded in the counter as against an average daily volume of 1.75 lakh shares in the past one quarter.
The stock hit a high of Rs 288.90 and a low of Rs 277.50 so far during the day. The stock had hit a 52-week high of Rs 304.50 on 14 January 2010 and a 52-week low of Rs 116.15 on 20 March 2009.
The mid-cap stock had underperformed the market over the past one month till 19 March 2010, gaining 5.68% as compared to the Sensex's 8.56% rise. It had also underperformed the market in the past one quarter, rising 0.97% as compared to the Sensex's return of 5.13%.
The company's equity capital is Rs 100 crore. Face value per share is Rs 5.
The current price of Rs 286 discounts the company's Q3 December 2009 annualized EPS of Rs 13.16, by a PE multiple of 21.73.
Under the terms, Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo, Biocon said in a filing with BSE.
US based Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals.
Biocon's net profit jumped 173.3% to Rs 65.80 crore on 36.8% rise in net sales to Rs 300.83 crore in Q3 December 2009 over Q3 December 2008.
Biocon is India's leading biotechnology enterprise. Over the past 28 years, it has evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, focused on healthcare.